Polymonoclonal (Not Polyclonal) Antibodies Derived from Convalescent Human B Cell Hybridomas Might Be a Better Therapeutic Option than Single Target Monoclonal Antibodies

Feroza Begum; Upasana Ray

doi:10.1021/acsptsci.0c00084

Polymonoclonal (Not Polyclonal) Antibodies Derived from Convalescent Human B Cell Hybridomas Might Be a Better Therapeutic Option than Single Target Monoclonal Antibodies

ACS Pharmacol Transl Sci. 2020 Jul 24;3(4):786-787. doi: 10.1021/acsptsci.0c00084. eCollection 2020 Aug 14.

Authors

Feroza Begum^{1

2}, Upasana Ray^{1

2}

Affiliations

¹ CSIR-Indian Institute of Chemical Biology, 4, Raja S.C., Mullick Road, Jadavpur, Kolkata, West Bengal 700032, India.
² Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.

Abstract

Both human B cell hybridoma technology and convalescent plasma therapy are promising immunological tools for therapeutic interventions. Here we propose using antibody producing B cells from convalescent SARS-CoV2 patients for developing human B cell hybridomas, and a combination of monoclonal antibodies against multiple immunogenic targets of SARS-CoV-2 spike protein might deliver an antibody cocktail for long-lasting therapeutic targeting.